Cargando…

Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway

BACKGROUND: Metabolic associated fatty liver disease (MAFLD) is a chronic disease characterized by excessive lipid deposition in the liver without alcohol or other clear liver-damaging factors. AMP-activated protein kinase (AMPK)/silencing information regulator (SIRT)1 signaling pathway plays an imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ning, Liu, Tong, Wang, Jianan, Xiao, Yingying, Zhang, Ying, Dai, Jun, Ma, Zhihong, Ma, Donglai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559901/
https://www.ncbi.nlm.nih.gov/pubmed/37808345
http://dx.doi.org/10.2147/DDDT.S417378
_version_ 1785117607896023040
author Zhang, Ning
Liu, Tong
Wang, Jianan
Xiao, Yingying
Zhang, Ying
Dai, Jun
Ma, Zhihong
Ma, Donglai
author_facet Zhang, Ning
Liu, Tong
Wang, Jianan
Xiao, Yingying
Zhang, Ying
Dai, Jun
Ma, Zhihong
Ma, Donglai
author_sort Zhang, Ning
collection PubMed
description BACKGROUND: Metabolic associated fatty liver disease (MAFLD) is a chronic disease characterized by excessive lipid deposition in the liver without alcohol or other clear liver-damaging factors. AMP-activated protein kinase (AMPK)/silencing information regulator (SIRT)1 signaling pathway plays an important role in MAFLD development. Si-Ni-San (SNS), a traditional Chinese medicine, has shown reducing hepatic lipid deposition in MAFLD rats, however, the underlying mechanisms of SNS are barely understood. PURPOSE: The aim of this research was to investigate the mechanisms of SNS in reducing hepatic lipid deposition in MAFLD rats by regulating AMPK/SIRT1 signaling pathways. METHODS: The components of SNS were determined by high performance liquid chromatography with mass spectrometry (HPLC-MS) analysis. MAFLD rats were induced by high-fat and high-cholesterol diet (HFHCD), and treated by SNS. SNS-containing serum and Compound C (AMPK inhibitor) were used to treat palmitic acid (PA)-induced HepG2 cells. To elucidate the potential mechanism, lipid synthesis-related proteins (SREBP-1c and FAS), fatty acid oxidation (PPARα and CPT-1), and AMPK/SIRT1 signaling pathway (p-AMPK and SIRT1) were assessed by Western blot. RESULTS: SNS improved serum lipid levels, liver function and reduced hepatic lipid deposition in MAFLD rats. SNS-containing serum reduced lipid deposition in PA-induced HepG2 cells. SNS could up-regulate protein expressions of PPARα, CPT-1, p-AMPK and SIRT1, and down-regulate protein expressions of SREBP-1c and FAS. Similar effects of SNS-containing serum were observed in PA-induced HepG2 cells. Meanwhile, Compound C weakened the therapeutic effects of SNS-containing serum on lipid deposition. CONCLUSION: SNS could reduce hepatic lipid deposition by inhibiting lipid synthesis and promoting fatty acid oxidation, which might be related with activating the AMPK/SIRT1 signaling pathway. This study could provide a theoretical basis for the clinical use of SNS to treat MAFLD.
format Online
Article
Text
id pubmed-10559901
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105599012023-10-08 Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway Zhang, Ning Liu, Tong Wang, Jianan Xiao, Yingying Zhang, Ying Dai, Jun Ma, Zhihong Ma, Donglai Drug Des Devel Ther Original Research BACKGROUND: Metabolic associated fatty liver disease (MAFLD) is a chronic disease characterized by excessive lipid deposition in the liver without alcohol or other clear liver-damaging factors. AMP-activated protein kinase (AMPK)/silencing information regulator (SIRT)1 signaling pathway plays an important role in MAFLD development. Si-Ni-San (SNS), a traditional Chinese medicine, has shown reducing hepatic lipid deposition in MAFLD rats, however, the underlying mechanisms of SNS are barely understood. PURPOSE: The aim of this research was to investigate the mechanisms of SNS in reducing hepatic lipid deposition in MAFLD rats by regulating AMPK/SIRT1 signaling pathways. METHODS: The components of SNS were determined by high performance liquid chromatography with mass spectrometry (HPLC-MS) analysis. MAFLD rats were induced by high-fat and high-cholesterol diet (HFHCD), and treated by SNS. SNS-containing serum and Compound C (AMPK inhibitor) were used to treat palmitic acid (PA)-induced HepG2 cells. To elucidate the potential mechanism, lipid synthesis-related proteins (SREBP-1c and FAS), fatty acid oxidation (PPARα and CPT-1), and AMPK/SIRT1 signaling pathway (p-AMPK and SIRT1) were assessed by Western blot. RESULTS: SNS improved serum lipid levels, liver function and reduced hepatic lipid deposition in MAFLD rats. SNS-containing serum reduced lipid deposition in PA-induced HepG2 cells. SNS could up-regulate protein expressions of PPARα, CPT-1, p-AMPK and SIRT1, and down-regulate protein expressions of SREBP-1c and FAS. Similar effects of SNS-containing serum were observed in PA-induced HepG2 cells. Meanwhile, Compound C weakened the therapeutic effects of SNS-containing serum on lipid deposition. CONCLUSION: SNS could reduce hepatic lipid deposition by inhibiting lipid synthesis and promoting fatty acid oxidation, which might be related with activating the AMPK/SIRT1 signaling pathway. This study could provide a theoretical basis for the clinical use of SNS to treat MAFLD. Dove 2023-10-03 /pmc/articles/PMC10559901/ /pubmed/37808345 http://dx.doi.org/10.2147/DDDT.S417378 Text en © 2023 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhang, Ning
Liu, Tong
Wang, Jianan
Xiao, Yingying
Zhang, Ying
Dai, Jun
Ma, Zhihong
Ma, Donglai
Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway
title Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway
title_full Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway
title_fullStr Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway
title_full_unstemmed Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway
title_short Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway
title_sort si-ni-san reduces hepatic lipid deposition in rats with metabolic associated fatty liver disease by ampk/sirt1 pathway
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559901/
https://www.ncbi.nlm.nih.gov/pubmed/37808345
http://dx.doi.org/10.2147/DDDT.S417378
work_keys_str_mv AT zhangning sinisanreduceshepaticlipiddepositioninratswithmetabolicassociatedfattyliverdiseasebyampksirt1pathway
AT liutong sinisanreduceshepaticlipiddepositioninratswithmetabolicassociatedfattyliverdiseasebyampksirt1pathway
AT wangjianan sinisanreduceshepaticlipiddepositioninratswithmetabolicassociatedfattyliverdiseasebyampksirt1pathway
AT xiaoyingying sinisanreduceshepaticlipiddepositioninratswithmetabolicassociatedfattyliverdiseasebyampksirt1pathway
AT zhangying sinisanreduceshepaticlipiddepositioninratswithmetabolicassociatedfattyliverdiseasebyampksirt1pathway
AT daijun sinisanreduceshepaticlipiddepositioninratswithmetabolicassociatedfattyliverdiseasebyampksirt1pathway
AT mazhihong sinisanreduceshepaticlipiddepositioninratswithmetabolicassociatedfattyliverdiseasebyampksirt1pathway
AT madonglai sinisanreduceshepaticlipiddepositioninratswithmetabolicassociatedfattyliverdiseasebyampksirt1pathway